Renal function one year after switching from Sandimmun® to Neoral®

被引：3

作者：

Seydoux, C ^{[1
]}

Stumpe, F ^{[1
]}

Hurni, M ^{[1
]}

Ruchat, P ^{[1
]}

Fischer, A ^{[1
]}

Mueller, X ^{[1
]}

von Segesser, L ^{[1
]}

Goy, JJ ^{[1
]}

机构：

[1] CHU Vaudois, Div Cardiol, CH-1011 Lausanne, Switzerland

来源：

CLINICAL TRANSPLANTATION | 1999年 / 13卷 / 06期

关键词：

cyclosporine; heart transplantation; renal function;

D O I：

10.1034/j.1399-0012.1999.130604.x

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

Background. The replacement of Sandimmun(R) by Neoral(R) in 1995 was thought to cause subsequent renal function deterioration due to the better bioavailability of the new drug. We prospectively analyzed the effect of a dose-to-dose drug replacement on renal function over 12 months. Methods and results. The renal function of 47 consecutive heart transplanted patients was prospectively evaluated before (T0), at 1 (T1), 3 (T3), and 12 (T12) months after drug replacement. Mean serum creatinine was not significantly different at T0 and T12 (142 +/- 55 and 154 +/- 60 mu mol/L, p = 0.1). We were able to reduce cyclosporine total and weight-indexed doses by, respectively, 11% and 14% between T0 and T12 (274 +/- 86 to 244 +/- 72 mg/d, p = 0.0003; and 3.7 +/- 1.4 to 3.2 +/- 1.2 mg/kg/d, respectively, p = 0.0005). Conclusions. This study demonstrates that the dose-to-dose replacement of Sandimmun by Neoral is feasible, with no direct influence on renal function over a 1-yr follow-up.

引用

页码：461 / 464

页数：4

共 50 条

[41] Low Dosing of Sandimmun® and Neoral® When Switching IV-PO Cyclosporin in Pediatric Bone Marrow Transplantation
N Bleyzac
G Souillet
S Rochegude
P Magron
N Djemel
P Maire
G Aulagner
Pediatric Research, 1999, 45 : 768 - 768
[42] Renal dysfunction in paediatric liver transplant recipients on cyclosporine: A comparison between neoral and sandimmun formulation.
Chai, PF
van Mourik, IDM
Lloyd, C
Davies, P
Kelly, DA
PEDIATRIC TRANSPLANTATION, 2005, 9 : 109 - 109
[43] Cyclosporine dose, blood levels, and renal allograft function after conversion from Sandimmune to Neoral.
Schmouder, RL
Rossi, SJ
Henry, SL
Leichtman, AB
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1996, 7 (09): : A3378 - A3378
[44] Limited sampling strategy to estimate exposure to cyclosporine A in renal allograft recipients treated with sandimmun-neoral
Serafinowicz, A
Gaciong, Z
Baczkowska, T
Rell, K
Lao, M
Walaszewski, J
TRANSPLANTATION PROCEEDINGS, 1996, 28 (06) : 3138 - 3139
[45] Cyclosporine pharmacokinetics in stable renal transplant patients: Effect of formulation sandimmun versus consupren versus neoral
Masri, MA
Barbari, A
Stephan, A
Kamel, G
Frem, G
Younan, F
Rizk, S
Moubarak, R
Karam, A
TRANSPLANTATION PROCEEDINGS, 1996, 28 (03) : 1318 - 1320
[46] Abbreviated kinetic profiles to estimate exposure to CyA in renal allograft recipients treated with sandimmun-neoral
Serafinowicz, A
Gaciong, Z
Majchrzak, J
Baczkowska, T
Nowacka, E
Gradowska, L
Rowinski, W
Lao, M
TRANSPLANTATION PROCEEDINGS, 1997, 29 (1-2) : 277 - 279
[47] Blood pressure control and renal function one-year after renal artery stenting
Przewlocki, T.
Roslawiecka, A.
Kablak-Ziembicka, A.
Rzeznik, D.
Kozanecki, A.
Pieniazek, P.
Musialek, P.
Tracz, W.
Podolec, P.
EUROPEAN HEART JOURNAL, 2010, 31 : 514 - 514
[48] Long-term experience with Sandimmun Neoral: Results in de novo and stable renal transplant patients after 24-month treatment
Korn, A
Farber, L
Maibucher, A
Buchholz, B
Offermann, G
TRANSPLANTATION PROCEEDINGS, 1997, 29 (07) : 2945 - 2947
[49] Natural history of parathyroid function one year after successful renal transplantation
Fourtounas, Costas
Karavias, Dionysios
Maroulis, Ioannis
Savidaki, Eirini
Mentza, Dimitra
Triga, Kostantina
Vlahojannis, Jannis G.
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 : 542 - 542
[50] Renal dysfunction in paediatric liver transplant recipients on longterm cyclosporin: Comparison between sandimmun and neoral formulation.
Van Mourik, I. D. M.
Chai, P. E.
Lloyd, C.
Davies, P.
Kelly, D. A.
PEDIATRIC TRANSPLANTATION, 2007, 11 : 96 - 96

← 1 2 3 4 5 →